phytonadione

Trade name: konakion

Small moleculeapproved

Approved

Sep 30, 1955

Phylloquinone is often called vitamin K1 or phytonadione. It is a fat-soluble vitamin that is stable to air and moisture but decomposes in sunlight. It is found naturally in a wide variety of green plants. Phylloquinone is also an antidote for coumatetralyl. Vitamin K is needed for the posttranslational modification of certain proteins, mostly required for blood coagulation. MEPHYTON (Phytonadione tablets) are indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity: anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; hypoprothrombinemia secondary to antibacterial therapy; hypoprothrombinemia secondary to administration of salicylates; hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed. MEPHYTON tablets possess the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). The prothrombin test is sensitive to the levels of three of these four factors II, VII, and X. Vitamin K is an essential cofactor for the gamma-carboxylase enzymes, which catalyze the posttranslational gamma-carboxylation of glutamic acid residues in inactive hepatic precursors of coagulation factors II (prothrombin), VII, IX, and X. Gamma-carboxylation converts these inactive precursors into active coagulation factors, which are secreted by hepatocytes into the blood. Supplementing with Phylloquinone results in a relief of vitamin K deficiency symptoms, which include easy bruisability, epistaxis, gastrointestinal bleeding, menorrhagia and hematuria. Oral phytonadione is adequately absorbed from the gastrointestinal tract only if bile salts are present. After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues. Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine. In normal animals and humans, phytonadione is virtually devoid of pharmacodynamic activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function; that is, to promote the hepatic biosynthesis of vitamin K-dependent clotting factors. MEPHYTON tablets generally exert their effect within 6 to 10 hours. — NCATS

Clinical trial activity

16 trials · 18 clinical orgs · 17 marketing orgs

Phase 1
2
Phase 2
9
Phase 3
5
Phase 4
1

Earliest trial started Jan 1, 2002 (NCT00150969)

Timeline

1950s

  1. Sep 30, 1955

    Roche — Earliest FDA Approval

  2. Sep 30, 1955

    Bausch Health Companies — NDA Secondary Org

  3. Sep 30, 1955

    Roche — NDA Organization

1960s

  1. Jun 28, 1960

    Teligent Pharmaceuticals — NDA Secondary Org

  2. Jun 28, 1960

    Pharmaceutical Associates — Marketing Organization

  3. Jun 28, 1960

    Pharmaceutical Associates — NDA Secondary Org

1970s

  1. Mar 1, 1976

    International Medication — Marketing Organization

1980s

  1. Apr 6, 1983

    Hospira — Marketing Organization

  2. Apr 6, 1983

    Hospira — NDA Secondary Org

2000s

  1. Jan 1, 2002

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. May 11, 2018

    Amneal Pharmaceuticals — Marketing Organization

  3. Feb 20, 2019

    Zydus Discovery DMCC — Marketing Organization

  4. May 22, 2019

    Dr. Reddy's Laboratories — Marketing Organization

2020s

  1. Apr 22, 2022

    Cipla — Marketing Organization

  2. Jul 28, 2023

    Sciegen Pharmaceticals — Marketing Organization

  3. Oct 12, 2023

    Agnitio — Marketing Organization

  4. Dec 10, 2024

    Gland Pharma Ltd — Marketing Organization

  5. Dec 19, 2024

    Hikma — Marketing Organization

  6. Apr 17, 2025

    Caplin Point Laboratories — Marketing Organization

  7. Sep 8, 2025

    Alembic — Marketing Organization

Indications

Mechanism of action

Combination products

Approval history

  • approvedPriority reviewSep 30, 1955

Chemistry & pharmacology

Loading structure…

SMILES

CC1=C(C/C=C(\C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=O)c2ccccc2C1=O
Mol. weight
450.71 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 2-methyl-3-[(2e)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone
  • 2-methyl-3-[(2e)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone
  • 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione
  • 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione
  • 3-phytylmenadione
  • 3-phytylmenadione
  • alpha-phylloquinone
  • alpha-phylloquinone
  • aquamephyton
  • aquamephyton
  • fitomenadiona
  • fitomenadiona
  • kanavit
  • konakion
  • konakion
  • konakion mm
  • konakion mm paed
  • mephyton
  • mephyton
  • mephyton
  • neokay
  • orakay
  • phyllochinon
  • phyllochinon
  • phytomenadionum
  • phytonadione
  • phytonadione
  • phytonadione
  • phytonadione
  • phytonadione
  • phytonadione
  • phytylmenadione
  • phytylmenadione
  • phytylmenadione
  • phytylmenaquinone
  • vitamin k1
  • vitamin k1
  • vitamin k1
  • vitamin k1
  • vitamin k1
  • vitamin k1
  • vitamin k1
  • vitamin k 1
  • vitamin k 1
  • α-phylloquinone
  • α-phylloquinone

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06385275Phase 1/Phase 2 (Phase 2)Dec 31, 2024Boston University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT02259647N/AJun 1, 2014Institute of Liver and Biliary Sciences, India
NCT02324686Phase 2Jan 1, 2014University of Toronto
NCT01742273Phase 3Oct 1, 2013RWTH Aachen University
NCT01528800Phase 2Nov 1, 2012Dr. Rachel Holden, Queen's University, Belfast
NCT01474460N/ASep 1, 2011Department of Veteran Affairs
NCT01638182N/AMar 1, 2011Maastricht University
NCT00990158Phase 3Jul 1, 2010McMaster University, University of Western Ontario
NCT01094444Phase 2May 31, 2010University of Southern Denmark
NCT01194778N/AOct 1, 2009Maastricht University
NCT00905229N/AMay 1, 2009Emek Medical Center
NCT00794755Phase 3Nov 1, 2008University of Ottawa
NCT01235325Phase 4Jul 1, 2008Health Research Board, Ireland, National University of Ireland
NCT02256813Phase 1Sep 1, 2005Boehringer Ingelheim
NCT00143715Phase 3Sep 1, 2004McMaster University, University of Western Ontario
NCT00150969Phase 3Jan 1, 2002Canadian Institutes of Health Research (CIHR), University of Toronto
Showing 16 of 16 trials
Page 1 / 1

Organizations

Research & Development (18)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Maastricht UniversityAcademic/Hospital2212009
McMaster UniversityAcademic/Hospital2012004
University of TorontoAcademic/Hospital2222002
University of Western OntarioAcademic/Hospital2212004
Boehringer IngelheimFor profit1112005
Boston UniversityAcademic/Hospital1112024
Canadian Institutes of Health Research (CIHR)Academic/Hospital1012002
Department of Veteran AffairsGovernment1112011
Dr. Rachel HoldenAcademic/Hospital1112012
Emek Medical CenterAcademic/Hospital1112009
Health Research Board, IrelandAcademic/Hospital1012008
Institute of Liver and Biliary Sciences, IndiaAcademic/Hospital1112014
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Government1012024
National University of IrelandAcademic/Hospital1112008
Queen's University, BelfastAcademic/Hospital1012012
RWTH Aachen UniversityAcademic/Hospital1112013
University of OttawaAcademic/Hospital1112008
University of Southern DenmarkAcademic/Hospital1112010
18 organizations
Page 1 / 1

Marketing (23)

OrganizationOrg typeRelationshipDate
AgnitioFor profitMKTGOct 12, 2023
AlembicFor profitMKTGSep 8, 2025
Amneal PharmaceuticalsFor profitMKTGMay 11, 2018
Amneal PharmaceuticalsFor profitSYNNov 4, 2025
Bausch Health CompaniesFor profitNDA2Sep 30, 1955
Caplin Point LaboratoriesFor profitMKTGApr 17, 2025
CiplaFor profitMKTGApr 22, 2022
Dr. Reddy's LaboratoriesFor profitSYNMay 22, 2019
Dr. Reddy's LaboratoriesFor profitMKTGMay 22, 2019
Gland Pharma LtdFor profitMKTGDec 10, 2024
Gland Pharma LtdFor profitSYNDec 10, 2024
GlaxoSmithKlineFor profitMKTG
HikmaFor profitMKTGDec 19, 2024
HospiraFor profitMKTGApr 6, 1983
HospiraFor profitNDA2Apr 6, 1983
International MedicationFor profitMKTGMar 1, 1976
Pharmaceutical AssociatesFor profitMKTGJun 28, 1960
Pharmaceutical AssociatesFor profitNDA2Jun 28, 1960
RocheFor profitNDASep 30, 1955
Sciegen PharmaceticalsFor profitMKTGJul 28, 2023
Teligent PharmaceuticalsFor profitNDA2Jun 28, 1960
Zydus Discovery DMCCFor profitMKTGFeb 20, 2019
Zydus Discovery DMCCFor profitSYNFeb 20, 2019